Cargando…
Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids ne...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757735/ https://www.ncbi.nlm.nih.gov/pubmed/35047878 http://dx.doi.org/10.3389/fmedt.2020.571030 |
_version_ | 1784632742674169856 |
---|---|
author | Xu, Ziyang Patel, Ami Tursi, Nicholas J. Zhu, Xizhou Muthumani, Kar Kulp, Daniel W. Weiner, David B. |
author_facet | Xu, Ziyang Patel, Ami Tursi, Nicholas J. Zhu, Xizhou Muthumani, Kar Kulp, Daniel W. Weiner, David B. |
author_sort | Xu, Ziyang |
collection | PubMed |
description | DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids neither replicate nor elicit vector-directed immune responses in hosts. While earlier work found the immune responses induced by DNA vaccines to be sub-optimal in larger mammals and humans, recent developments in key synthetic DNA and electroporation delivery technologies have now allowed DNA vaccines to elicit significantly more potent and consistent responses in several clinical studies. This paper will review findings from the recent clinical and preclinical studies on DNA vaccines targeting emerging infectious diseases (EID) including COVID-19 caused by the SARS-CoV-2 virus, and the technological advancements pivotal to the improved responses—including the use of the advanced delivery technology, DNA-encoded cytokine/mucosal adjuvants, and innovative concepts in immunogen design. With continuous advancement over the past three decades, the DNA approach is now poised to develop vaccines against COVID-19, as well as other EIDs. |
format | Online Article Text |
id | pubmed-8757735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87577352022-01-18 Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases Xu, Ziyang Patel, Ami Tursi, Nicholas J. Zhu, Xizhou Muthumani, Kar Kulp, Daniel W. Weiner, David B. Front Med Technol Medical Technology DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids neither replicate nor elicit vector-directed immune responses in hosts. While earlier work found the immune responses induced by DNA vaccines to be sub-optimal in larger mammals and humans, recent developments in key synthetic DNA and electroporation delivery technologies have now allowed DNA vaccines to elicit significantly more potent and consistent responses in several clinical studies. This paper will review findings from the recent clinical and preclinical studies on DNA vaccines targeting emerging infectious diseases (EID) including COVID-19 caused by the SARS-CoV-2 virus, and the technological advancements pivotal to the improved responses—including the use of the advanced delivery technology, DNA-encoded cytokine/mucosal adjuvants, and innovative concepts in immunogen design. With continuous advancement over the past three decades, the DNA approach is now poised to develop vaccines against COVID-19, as well as other EIDs. Frontiers Media S.A. 2020-10-21 /pmc/articles/PMC8757735/ /pubmed/35047878 http://dx.doi.org/10.3389/fmedt.2020.571030 Text en Copyright © 2020 Xu, Patel, Tursi, Zhu, Muthumani, Kulp and Weiner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medical Technology Xu, Ziyang Patel, Ami Tursi, Nicholas J. Zhu, Xizhou Muthumani, Kar Kulp, Daniel W. Weiner, David B. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title | Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title_full | Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title_fullStr | Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title_full_unstemmed | Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title_short | Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases |
title_sort | harnessing recent advances in synthetic dna and electroporation technologies for rapid vaccine development against covid-19 and other emerging infectious diseases |
topic | Medical Technology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757735/ https://www.ncbi.nlm.nih.gov/pubmed/35047878 http://dx.doi.org/10.3389/fmedt.2020.571030 |
work_keys_str_mv | AT xuziyang harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT patelami harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT tursinicholasj harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT zhuxizhou harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT muthumanikar harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT kulpdanielw harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases AT weinerdavidb harnessingrecentadvancesinsyntheticdnaandelectroporationtechnologiesforrapidvaccinedevelopmentagainstcovid19andotheremerginginfectiousdiseases |